5th Gene Therapy for Ophthalmic Disorders Summit
Evvnt Promotion / evvnt
Archivo
10.09.2024 - 12.09.2024 Wyndham Boston Beacon Hill, 5 Blossom Street, 02114 Boston, Massachusetts, USA
Time: 8:00 AM - 5:00 PM
Temas de la conferencia
Ophthalmic drug developers are unlocking the full potential of gene therapy. Crucial lessons learnt from both clinical successes and failures, coupled with recent improvements in development and delivery, means that the space is poised to capitalize on the significant potential of the eye as a target for genetic medicine approaches.
Ophthalmic drug developers are unlocking the full potential of gene therapy. Crucial lessons learnt from both clinical successes and failures, coupled with recent improvements in development and delivery, means that the space is poised to capitalize on the significant potential of the eye as a target for genetic medicine approaches.
Organizador profesional (PCO)
Hanson Wade
Hanson Wade
Observaciones
URL:
Brochure: https://go.evvnt.com/2478440-2?pid=4832
Speakers: Abraham Scaria, Chief Scientific Officer, Beacon Therapeutics, Adam Silverman, Vice President - Protein Sciences, Spotlight Therapeutics, and more
URL:
Brochure: https://go.evvnt.com/2478440-2?pid=4832
Speakers: Abraham Scaria, Chief Scientific Officer, Beacon Therapeutics, Adam Silverman, Vice President - Protein Sciences, Spotlight Therapeutics, and more
Información e inscripción:
https://go.evvnt.com/2478440-3?pid=4832
Ms. Mara Mihailovic
Medicina General
Cantacto organizador
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Going International fomenta el acceso a la educación y a la formación continua independientemente de fronteras sociales, geográficas y nacionales."
